Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2023-05-06

Clinical Trial Update: 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia [Phase 3]

View source ↗

Summary

Phase 3 trial of BIIB074 for trigeminal neuralgia was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BIIB074

Snippet

Sponsor: Biogen | Conditions: Trigeminal Neuralgia | Phase 3 | Status: WITHDRAWN